News headlines about ARGENX (NASDAQ:ARGX) have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ARGENX earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.8078474870698 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
ARGENX (ARGX) opened at $31.00 on Monday. ARGENX has a twelve month low of $17.33 and a twelve month high of $35.71.
Several research firms have commented on ARGX. Wedbush reaffirmed an “outperform” rating and issued a $41.00 price target (up previously from $26.00) on shares of ARGENX in a report on Thursday, November 16th. They noted that the move was a valuation call. Zacks Investment Research cut ARGENX from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Cowen reaffirmed a “buy” rating on shares of ARGENX in a report on Thursday, August 24th.
ARGENX Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.